Resumo

PEREZ MORAN, MªJ; CABANES MARISCAL, MªÁ; APARICIO HERNANDEZ, R  e  GARCIA LUQUE, A. Positive assessment of drugs: May, June and July 2018. Sanid. Mil. [online]. 2018, vol.74, n.4, pp.236-247. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712018000400005.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in May, June and July of 2018, and considered of interest to the healthcare professional, are reviewed here. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Abemaciclib (Verzenios®); Adalumumab (Halimatoz®, Hefiya®, Hyrimoz®, Hulio®); Binimetinib (Mektovi®); Caplacizumab (Cablivi®); Durvalumab (Imfinzi®); Encorafenib (Braftovi®); Erenumab (Aimovig®); Eravaciclina (Xevara®); Inotersen (Tegsedi®); Lesinurad/alopurinol (Duzallo®); Melatonina(slenyto®); Metreleptina (Myaleota®); Neratinib (Nerlynx®); Patisiran (Onpattro®); Pegfilgrastim (Pelgraz®); Pegfilgrastim (Udenyca®); Tezacaftor/ivacaftor (Symkevi®); Tildrakizumab (Ilumetri®); Tisagenlecleucel (Kymriah®); Trastuzumab (Trazimera®); Vestronidasa alfa (Mepsevii®); Vigabatrina (Kigabeq®); Vonicog alfa (Veyvondi®); Daunorubicina/citarabina (Vyxeos); Axicabtagen ciloleucel (Yescarta®).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )